Skip to main content
SONX
OTC Life Sciences

Sonendo Refinances Debt, Launches Flex Program, and Cuts EBITDA Loss 60%

Tom Rudovsky · Reported by BusinessWire
Sentiment info
Positive
Importance info
7
Price
$0.58
Mkt Cap
$247.893K
52W Low
$0
52W High
$3,400
52W Position
Off High info
100% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

Summary

Sonendo announced a $15.5M senior secured term loan plus $4.5M committed capital and $5.0M subordinated financing, refinancing its existing $13.7M facility. The company also rolled out the Flex Program, a new commercial model that removes upfront equipment cost for GentleWave adoption. Preliminary H1 2026 revenue was $14.5M with Adjusted EBITDA loss of $2.8M, a 60% improvement from $6.9M a year earlier. The refinancing strengthens the balance sheet and provides additional liquidity, while the Flex Program aims to accelerate adoption. These moves support the company's stated path toward cashflow break-even.

At the time of this announcement, SONX was trading at $0.58 on OTC in the Life Sciences sector, with a market capitalization of approximately $247.9K. The 52-week trading range was $0.00 to $3,400.00. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: BusinessWire.


Price Chart

Share this article

Copied!

SONX - Latest Insights